Vivus (VVUS +9%) spikes to a year high on the back of the the FDA's approval of Arena...

|By:, SA News Editor

Vivus (VVUS +9%) spikes to a year high on the back of the the FDA's approval of Arena Pharmaceuticals' (ARNA +38%) weight-loss drug Belviq. Regulators are set to make a decision on its Qnexa diet drug on July 17.